Hurler syndrome is a rare, inherited condition in which the body lacks an enzyme needed to break down certain complex sugar molecules. Without this enzyme, those molecules build up inside cells throughout the body, progressively damaging the brain, heart, liver, bones, and other organs. Without treatment, children with Hurler syndrome typically do not survive past their first decade of life. It is the most severe form of a group of conditions called mucopolysaccharidosis type I (MPS I).
What Causes Hurler Syndrome
Every cell in your body contains small recycling compartments called lysosomes, which break down and dispose of worn-out molecules. One of the enzymes inside these compartments is alpha-L-iduronidase, and children with Hurler syndrome are born without it. This enzyme’s job is to break down two specific types of complex sugar chains called glycosaminoglycans (GAGs). When the enzyme is missing, GAGs accumulate inside cells in enormous quantities.
The buildup is not limited to one tissue. GAGs deposit in the heart, spleen, liver, muscles, connective tissues, joints, and the central nervous system, causing those organs to enlarge, thicken, and lose function over time. The condition is inherited in an autosomal recessive pattern, meaning a child must receive one copy of the faulty gene from each parent to develop the disease.
Early Signs and Physical Symptoms
Babies with Hurler syndrome often appear healthy at birth, but signs begin emerging within the first year. Research tracking early disease progression found that gross motor function was the weakest area of development, with deficits becoming apparent during the first year of life. Delays in both receptive and expressive language also tend to surface before the child’s first birthday.
As GAGs accumulate, a distinctive pattern of physical features develops:
- Facial features: A flat nasal bridge, thick lips, and an enlarged tongue give children a characteristic coarse facial appearance.
- Skeletal changes: Short stature, abnormal bone shape, joint stiffness, and spinal abnormalities become increasingly pronounced.
- Organ enlargement: The liver and spleen grow significantly larger as storage material builds up inside them.
- Hernias: Umbilical and inguinal hernias are common.
- Eyes: Corneal clouding develops, causing progressive vision loss.
- Hearing: Progressive hearing loss affects many children.
Carpal tunnel syndrome can also develop, restricting hand mobility and function. Some children develop hydrocephalus, a dangerous increase in fluid pressure inside the skull.
How It Affects the Brain
The neurological impact of Hurler syndrome is what distinguishes it from milder forms of MPS I. Cognitive development begins deviating from typical patterns at roughly 9 months of age. Children may reach early milestones on time or only slightly late, but then plateau and begin to regress. Without treatment, cognitive impairment becomes severe, and children lose skills they had previously gained.
This timeline matters enormously for treatment decisions. A study by Poe and colleagues found that patients who received a stem cell transplant before 9 months of age showed relatively normal cognitive development afterward, while those transplanted later experienced long-term deficits. In other words, the transplant can halt the decline but struggles to reverse damage that has already occurred.
How It Is Diagnosed
Hurler syndrome is now included on the Recommended Uniform Screening Panel (RUSP) for newborn screening in the United States. During screening, a machine measures the activity of the enzyme alpha-L-iduronidase in a newborn’s blood sample. Some screening programs also measure GAG levels. Babies with low enzyme activity and high GAG levels are flagged for follow-up testing, which typically involves additional blood and urine tests along with genetic testing to confirm the diagnosis and identify the specific gene mutations involved.
Newborn screening has been a significant step forward because the window for the most effective treatment is narrow. Before routine screening, many children were not diagnosed until physical symptoms became obvious, often after irreversible brain damage had already begun.
Stem Cell Transplant: The Primary Treatment
The cornerstone treatment for Hurler syndrome is a stem cell transplant (also called hematopoietic stem cell transplantation, or HSCT), ideally performed before the age of 2. Donor stem cells engraft in the child’s body and produce a continuous supply of the missing enzyme, which is then distributed to tissues throughout the body. Critically, cells derived from the transplant can cross into the brain, something that intravenously delivered enzyme cannot do. This makes transplantation the only established treatment that addresses the neurological component of the disease.
The transplant itself is a demanding process. Children receive chemotherapy to make room for the donor cells, followed by the infusion and a period of recovery during which the immune system rebuilds. Outcomes depend heavily on timing, the quality of the donor match, and how much enzyme the engrafted cells ultimately produce. Low enzyme levels after transplant have been linked to worse cognitive outcomes.
Enzyme Replacement Therapy
Enzyme replacement therapy (ERT) delivers a manufactured version of the missing enzyme through weekly intravenous infusions. In clinical trials, treated patients showed meaningful improvements in lung function, walking endurance (averaging about 38 meters farther on a six-minute walk test compared to placebo), and liver size reduction. Sleep apnea also improved significantly. Urinary GAG levels dropped, indicating that the enzyme was reaching tissues and clearing stored material.
ERT has clear limitations, though. It did not produce measurable improvements in overall physical disability scores, and its effect on corneal clouding is minimal. Most importantly, the enzyme delivered through an IV does not cross the blood-brain barrier, so it cannot address cognitive decline. For this reason, ERT is often used as a bridge therapy to stabilize a child’s condition before transplant, or as an ongoing treatment for patients with milder forms of MPS I who do not have significant brain involvement.
Managing Ongoing Complications
Even after a successful transplant, many children with Hurler syndrome continue to face complications that require specialized care. Corneal clouding is one of the most persistent problems. Neither ERT nor stem cell transplant effectively clears the GAG deposits from the cornea, and the only definitive treatment for significant corneal clouding is a corneal transplant. Photochromatic glasses can help ease light sensitivity in the meantime.
Joint stiffness, skeletal abnormalities, and heart valve problems often persist or progress despite treatment and may require ongoing monitoring, physical therapy, or surgical intervention over the course of a child’s life. Hearing aids or other support for hearing loss are commonly needed as well.
Life Expectancy and Outlook
Without any treatment, Hurler syndrome is fatal in childhood, with most children dying within the first decade due to progressive organ failure. Stem cell transplant performed early has dramatically changed that trajectory. Children who receive a successful transplant before age 2, particularly before 9 months, can survive into adulthood with preserved cognitive function, though they typically still require ongoing medical management for skeletal and other complications.
Gene Therapy on the Horizon
A phase 1-2 clinical trial published in the New England Journal of Medicine tested a new approach: instead of transplanting donor cells, researchers collected a child’s own stem cells, genetically engineered them to produce the missing enzyme, and infused them back. The results in eight children were striking. Their blood enzyme activity reached 3 to 12 times the normal level. Previously undetectable enzyme activity in spinal fluid became measurable, and GAG levels in the brain dropped. Children showed stable cognitive performance, continued motor development, improved joint flexibility, and normal growth.
The advantage of this approach is twofold. Using a child’s own cells eliminates the risk of graft rejection, and the engineered cells appear to produce far more enzyme than a standard donor transplant provides. The therapy is still experimental, but it represents a potential shift in how Hurler syndrome could be treated in the coming years.